Skip to content
10-K

Annual Report

Grace Therapeutics, Inc. GRCE

0001140361-26-025662

← back to feed
Filed
Jun 18, 2026 7:31 AM ET
Period of report
Jun 15, 2026

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2026 · Jun 15, 2026 16.27M sh
Shares Diluted FY 2026 · Mar 31, 2026 16.51M sh
Operating Cash Flow FY 2026 · Mar 31, 2026 −$8.87M
Cash And Equivalents FY 2026 · Mar 31, 2026 $16.98M
Stockholders Equity FY 2026 · Mar 31, 2026 $63.9M
Current Liabilities FY 2026 · Mar 31, 2026 $2.15M
Total Liabilities FY 2026 · Mar 31, 2026 $2.76M
Current Assets FY 2026 · Mar 31, 2026 $17.38M
Total Assets FY 2026 · Mar 31, 2026 $66.65M
Eps Diluted FY 2026 · Mar 31, 2026 −$0.47
Eps Basic FY 2026 · Mar 31, 2026 −$0.47
Sga Expense FY 2026 · Mar 31, 2026 $8.67M
Rd Expense FY 2026 · Mar 31, 2026 $2.41M
Net Income FY 2026 · Mar 31, 2026 −$7.79M
Operating Income FY 2026 · Mar 31, 2026 −$11.08M